Trimetrexate

Overview

Trimetrexate (CI-898) is an antibiotic , also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC 50 values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate can also inhibit the growth of various cancer cells. Trimetrexate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Dihydrofolate reductase (DHFR) | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > Antifolate | Products > Signaling Pathways > Parasite | Products > Signaling Pathways > Bacterial

Product Information

• Catalog No.: HY-10373
• CAS No.: 52128-35-5
• Molecular Formula: C19H23N5O3
• Molecular Weight: 369.42
• Purity: 99.60%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
• Availability: In-stock

Source

Original product source